Menu
← Oncology Approval Tracker
FDA DECISION ·
Zimrixby
rituximab-cdxx · Dr. Reddy’s Laboratories
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Rituxan biosimilar with labeled adult oncology uses in non-Hodgkin lymphoma and CLL, including specified combination, monotherapy and maintenance settings.
LAMPGEN ANALYSIS
Why it matters
A rituximab biosimilar can expand purchasing options for established CD20-directed regimens. Its approval rests on biosimilarity to the reference product.
What research teams should watch
Verify the specific oncology use in the product label and capture product identity in infusion records and safety reporting.
PRIMARY RECORDS